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Introduction: Administration of mesenchymal stem cells (MSCs) represents a promising treatment option for
patients suffering from immunological and degenerative disorders. Accumulating evidence indicates that the healing
effects of MSCs are mainly related to unique paracrine properties, opening opportunities for secretome-based therapies.
Apart from soluble factors, MSCs release functional small RNAs via extracellular vesicles (EVs) that seem to convey
essential features of MSCs. Here we set out to characterize the full small RNAome of MSC-produced exosomes.
Methods: We set up a protocol for isolating exosomes released by early passage adipose- (ASC) and bone
marrow-MSCs (BMSC) and characterized them via electron microscopy, protein analysis and small RNA-sequencing.
We developed a bioinformatics pipeline to define the exosome-enclosed RNA species and performed the first
complete small RNA characterization of BMSCs and ASCs and their corresponding exosomes in biological replicates.
Results: Our analysis revealed that primary ASCs and BMSCs have highly similar small RNA expression profiles
dominated by miRNAs and snoRNAs (together 64-71 %), of which 150–200 miRNAs are present at physiological levels.
In contrast, the miRNA pool in MSC exosomes is only 2-5 % of the total small RNAome and is dominated by a minor
subset of miRNAs. Nevertheless, the miRNAs in exosomes do not merely reflect the cellular content and a defined set
of miRNAs are overrepresented in exosomes compared to the cell of origin. Moreover, multiple highly expressed
miRNAs are precluded from exosomal sorting, consistent with the notion that these miRNAs are involved in functional
repression of RNA targets. While ASC and BMSC exosomes are similar in RNA class distribution and composition, we
observed striking differences in the sorting of evolutionary conserved tRNA species that seems associated with the
differentiation status of MSCs, as defined by Sox2, POU5F1A/B and Nanog expression.
Conclusions: We demonstrate that primary MSCs release small RNAs via exosomes, which are increasingly implicated
in intercellular communications. tRNAs species, and in particular tRNA halves, are preferentially released and their
specific sorting into exosomes is related to MSC tissue origin and stemness. These findings may help to understand
how MSCs impact neighboring or distant cells with possible consequences for their therapeutic usage.* Correspondence: s.baglio@vumc.nl; d.pegtel@vumc.nl
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Mesenchymal stem cells (MSCs) are intensively studied
because they exhibit unique biological properties in vivo
that are exploited for the treatment of many pathological
conditions, most notably bone defects, degenerative ill-
nesses, and autoimmunity [1].
MSCs are adult multipotent stem cells with self-
renewal potential [2] that can differentiate into alternate
phenotypes of the mesenchymal germ layer, namely oste-
oblasts, chondrocytes, and adipocytes [3]. The most
common source of MSCs is the bone marrow [4, 5];
however, MSCs reside in many other tissues, notably
adipose tissue, which is highly relevant because it is an
easy accessible abundant source of stem cells [6].
Whether MSCs from different sources can be considered
as the same cell type and whether distinct environments
may influence their phenotype and function are still
under debate [7, 8].
Recent advances suggest that the beneficial effects of
MSCs derive from secreted factors rather than from
their tissue intercalation and differentiation. The MSC
secretome drives organ healing by inducing a shift from
proinflammatory to anti-inflammatory cytokine produc-
tion at the site of injury [9–11]. These observations sup-
port the development of cell-free, secretome-based
therapies that circumvent the risks associated with stem
cell-based therapies such as immune-mediated rejection,
accumulation of genomic alterations, and senescence-
induced genetic instability [12–14], and might require
simpler safety regulations compared with their cell coun-
terparts for clinical use [11].
The interest behind the MSC secretome goes beyond
its application in tissue repair. Indeed, MSCs are strong
contributors to tumor growth and progression in differ-
ent cancer types [15–17], although anti-tumor activities
have also been reported underscoring their pleiotropic
properties [18, 19]. A unique aspect of MSCs is that they
strongly respond to inflammatory signals causing homing
to active tumor sites, where they provide paracrine sur-
vival, proangiogenic and immune-modulatory signals,
similar to those that promote wound healing. Previous
studies have focused on characterizing MSC-produced
soluble factors (i.e. cytokines, chemokines, and growth
factors). However, it is now clear that, in addition to sol-
uble factors, extracellular vesicles (EVs) are a key instru-
ment in cell–cell communication [20]. Among the many
subtypes of EVs, endosome-derived exosomes have
emerged as physiologically relevant and powerful com-
ponents of the MSC secretome [11, 12, 21].
Exosomes are nano-sized EVs with remarkable physio-
logical properties, originating through inward budding
of the limiting membrane of late endosomes called mul-
tivesicular bodies (MVBs). Upon fusion of MVBs with
the plasma membrane, exosomes are released into theextracellular milieu and can be either taken up by target
cells residing in the microenvironment or carried to dis-
tant sites via biological fluids. Besides transporting charac-
teristic protein and lipid signatures, exosomes package
nucleic acids, most notably various RNA species with
regulatory functions [22]. Arguably the most studied class
of exosome-enclosed RNAs is the class of microRNAs
(miRNAs), which function in repressing their target
mRNAs in recipient cells in vitro [23–26] and in vivo [27].
However, we recently showed in B cells that miRNAs only
account for a fraction of the exosomal RNA. Indeed, other
noncoding transcripts, including repeats and structural
RNAs, complete the exosomal RNA repertoire produced
in B cells but also in other cell types [28, 29].
MSC-derived vesicles own remarkable properties typ-
ical of functional MSCs. Kordelas et al. [11] demon-
strated the clinical efficacy of MSC exosomes to treat
therapy-refractory graft-versus-host disease. Moreover,
MSC-EVs regulate neurite outgrowth [30], promote
angiogenesis both in vitro and in vivo [31], reduce myo-
cardial ischemia/reperfusion injury [21], and repair acute
kidney injury [32, 33]. Thus, it is reasonable to postulate
that MSC-EVs transport key MSC-associated molecules
which change the physiology of target cells in a specific
manner. Proteomic analysis suggests that MSC-EVs or
subclasses thereof contain critical surface markers and
signaling molecules characteristic of the MSCs [34].
Moreover, prior quantitative PCR profiling analysis [35]
showed that while some miRNAs are present both in
MSCs and in their corresponding microvesicles, others
are selectively represented.
To optimally understand and exploit the clinical po-
tential of adult MSC-derived exosomes, it is important
to define the relevant functional molecules they enclose.
Comprehensive information on the complete RNA con-
tent of MSC exosomes is currently not available, and
whether adult MSCs from different sources share similar
small RNA repertoires or whether their content is differ-
ent remains unknown.
Here we describe the first comprehensive deep-
sequencing analysis of the small RNA profile of exosomes
released by adult MSCs from two different sources:
adipose-derived MSCs (ASCs) and bone marrow-derived
MSCs (BMSCs). Our analysis of the exosomal content is
useful for understanding how MSCs impact their micro-
environment in resident niches and upon homing to dam-
aged and inflamed tissues, which may have consequences
for their therapeutic usage.
Materials and methods
Cell culture
Human adipose tissue samples from elective plastic sur-
gery were obtained from the Department of Plastic Sur-
gery of Tergooi Hospital after the approval of the Medical
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Netherlands) and written informed consent. Adipose
tissue was processed within 24 hours as described previ-
ously [36]. Briefly, adipose tissue was minced using a
surgical scalpel and digested with 0.1 % collagenase A
(Roche Mannheim, Germany) in phosphate-buffered
saline (PBS) 1 % bovine serum albumin (BSA; Roche
Diagnostics) under continuous shaking for 45 minutes
at 37 °C. After Ficoll density separation (Lymphoprep;
Axis-Shield, Oslo, Norway) cells were seeded at a dens-
ity of 100,000 cells/cm2. The bone marrow of patients
undergoing hip replacement was obtained from the
Rizzoli Orthopedic Institute after the approval of the
Comitato Etico dell’Istituto Ortopedico Rizzoli (Bologna,
Italy) and written informed consent. Mononuclear cells
were isolated by Ficoll Hystopaque gradient (Sigma-
Aldrich, Milan, Italy) and seeded at a density of 250,000
cells/cm2. After 4 days, nonadherent cells were removed
and fresh medium was added to the cultures. ASCs and
BMSCs were expanded in alpha-minimum essential
medium (α-MEM; Lonza, Breda, The Netherlands) con-
taining 100 U/ml penicillin, 100 μg/ml streptomycin
(Gibco, Bleiswijk, the Netherlands), and 10 % fetal
bovine serum (FBS) or 5 % platelet lysate (PL) [37]
and 10 U/ml heparin (Leo Pharma, Amsterdam, the
Netherlands), in a humidified atmosphere of 5 % CO2 at
37 °C. The expression of typical MSC surface markers
was analyzed by fluorescence-activated cell sorting
(FACS), and the ability of the MSCs to undergo osteo-
genic differentiation was assessed by Alizarin red stain-
ing upon induction with ascorbic acid, dexamethasone,
and β-glycerophosphate [38].
Exosome isolation
MSC exosomes were collected from approximately 3.2 ×
107 cells at early passages (passages 2–3). Once MSC cul-
tures reached 70 % confluence, cells were cultured for 24–
48 hours in α-MEM containing exosome-depleted FBS or
PL. Exosome-depleted FBS and PL were obtained by over-
night centrifugation at 70,000 × g at 4 °C. Exosomes were
isolated as described previously [39]. Briefly, MSC condi-
tioned medium was centrifuged twice at 500× g for 10
minutes, twice at 2000 × g for 15 minutes and twice at
10,000 × g for 30 minutes. The supernatant was then
transferred to Ultra-Clear tubes and centrifuged at 70,000
× g for 1 hour at 4 °C in a SW32Ti rotor (Beckman Coulter
Inc., Woerden, The Netherlands). The exosome-containing
pellet was washed with PBS and centrifuged at 70,000 × g
for 1 hour. The pellet was then carefully resuspended in
200 μl PBS and used immediately or stored at −80 °C.
Confocal laser scanning microscopy
For confocal laser scanning microscopy analysis, MSCs
were seeded on poly-L-lysine-coated (Sigma-Aldrich)coverslips, fixed with 4 % paraformaldehyde, perme-
abilized with 0.1 % Triton-X 100 and blocked with PBS
10 % FBS (30 minutes). Slides were incubated with the
primary antibodies against CD63 (BD Biosciences,
Breda, The Netherlands) or EEA1 (Cell Signaling,
Leiden, The Netherlands) and then with rabbit anti-
mouse fluorescein isothiocyanate (FITC) antibody
(DAKO, Heverlee, Belgium) for 30 minutes at room
temperature. LysoTracker red (Molecular Probes, Bleis-
wijk, The Netherlands) was incubated with living cells be-
fore fixation. All stainings were imaged with a Leica
DMRB microscope (Leica, Son, The Netherlands). Images
were obtained through sequential scanning with the pin-
hole set at 1AE (standard). Fluorophores were excited
using 488 nm (FITC) and 561 nm (Alexa594) laser lines.
Western blotting
For western blot analysis, cells were lysed with RIPA
buffer containing protease inhibitor cocktail (Roche),
and the protein concentration was determined by BCA
assay (Pierce, Etten-Leur, The Netherlands). Cell lysates
and exosome preparations diluted in sample buffer
were run on a 10 % SDS gel and blotted on a nitrocellu-
lose membrane (GE Healthcare, Eindhoven, The
Netherlands). Membranes were incubated with monoclo-
nal antibodies against CD63, CD81, or cytochrome C (BD
Biosciences) and horseradish peroxidase-conjugated rabbit
anti-mouse secondary antibody (DAKO). Gels for CD63
and CD81 detection were run under nonreducing
conditions.
Transmission electron microscopy
Cell pellets were fixed with 2.5 % glutaraldehyde (Merck
KGaA, Darmstadt, Germany) in phosphate buffer for 2
hours, post fixed with 1 % osmium tetroxide, dehydrated
in a graded series of ethanol, and embedded in Epon
(Electron Microscopy Sciences, Hatfield, PA,USA). Ul-
trathin sections were stained with uranyl acetate and
lead citrate. Exosome preparations were mixed with an
equal volume of 4 % paraformaldehyde (Sigma) in phos-
phate buffer. Then 5 μl solution were deposited on 200
mesh Formvar-carbon-coated electron microscopy (EM)
nickel grids and left to adsorb for 20 minutes at room
temperature. Samples were fixed with 1 % glutaralde-
hyde (Merck) in phosphate buffer, contrasted with ur-
anyl oxalate (pH 7.0), and embedded in a mixture of 4 %
uranyl acetate and 2 % methyl cellulose (25 cps; Sigma)
in a 1:9 ratio on ice. Grids were then removed with
stainless steel loops and the excess fluid was blotted with
filter paper to ensure an appropriate thickness of the
methyl cellulose film. After drying, grids were examined
with a Zeiss EM109 transmission electron microscope
(Zeiss, Oberkochen, Germany). Images were captured
using a Nikon digital camera Dmx 1200F (Nikon
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Corporation).
RNA isolation, RT-PCR, and generation of libraries for
small RNA sequencing
Total RNA was isolated using Trizol Reagent (Invitrogen,
Breda, The Netherlands) as described previously [39]. Exo-
some preparations were pretreated with RNase A (Sigma-
Aldrich) at a final concentration of 400 ng/μl at 37 °C for 1
hour to degrade unprotected RNAs. The RNA quantity
and purity were assessed with the Agilent 2100 Bioanalyzer
system (Agilent, Amstelveen, The Netherlands). The ex-
pression analyses of differentiation and stemness-related
genes were carried out using SYBR Green PCR master mix
(Roche) in a LightCycler 480 real-time PCR system
(Roche). Results were normalized with respect to glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) according
to the ΔΔCt method [40]. cDNA libraries for sequencing
were prepared using the TruSeq Small RNA Sample Prep-
aration Kit (Illumina, Eindhoven, The Netherlands) follow-
ing the manufacturer’s instructions. Amplified cDNA
constructs were purified on 6 % PAGE gel and DNA mole-
cules corresponding to 15–90 nucleotide transcripts were
excised, eluted from gel, and concentrated by ethanol pre-
cipitation. Libraries were validated on the Bioanalyzer
using the High Sensitivity DNA Chip (Agilent) and equi-
molarly pooled for the sequencing run. Sequencing was
performed on a HiSeq 2000 (Illumina) paired end 100 cycle
(PE100) run.
Assignment of features to reads
Adapter sequences were trimmed from the 3′ ends of
raw data using cutadapt (v1.1) [41] and the parameters
“-O 12 -e 0..25”. Trimmed reads were aligned to the hu-
man genome (build hg19) using bowtie (v2.0.6) [42], and
multiple valid alignments per read were reported (up to
50) using the parameters “–seed 42 –gbar 100 -D 10 -R
2 -L 20 -N 0 -i C,1 -k 50 –score-min L,0,-0.4”. For each
read, only the alignments with the best score were used
in subsequent analyses.
Several sources of genome annotation were used.
GENCODE v.15 [43] was used, but transcripts with a
total length larger than 120 were excluded, as well as
genes of type “sense_intronic”, “sense_overlapping”, and
“miRNA”. For miRNAs, annotations from miRBase
(v.19) [44] were used, for both primary and mature tran-
script annotations. tRNA annotations were obtained
from GENCODE/tRNA and were supplemented with
metadata from GtRNAdb [45]. piRNA annotations from
the piRNA database [46] were used while collapsing
overlapping annotations into clusters. Repeat annota-
tions and metadata from RepeatMasker were obtained
from the UCSC (University of California Santa Cruz)
genome browser (27 March 2013) [47].Using the (possibly multiple) alignments per read, and
the annotations described before, the set of (possibly
partially) overlapping genes was determined. In the case
that the set of genes all belonged to a certain “feature-
type” (i.e. RNA type), the featuretype was assigned to
that read. In the case that the featuretype was ambigu-
ous, the following steps were taken. If the length of the
read was larger than 25 nucleotides, the featuretype
“miRNA, processed” was eliminated; otherwise, the fea-
turetype “miRNA, premature” was eliminated. If the
length of the read was larger than 32 nucleotides, the
featuretype “piRNA” was eliminated. If at this point the
featuretype could be determined unambiguously, this
featuretype was assigned. Otherwise, if there were two
possible featuretypes, of which one was a repeat, the
nonrepeat featuretype was assigned to the read. If this
was not the case, and the read had two or more possible
alignments, all featuretypes which were indicated by only
one alignment were eliminated. Again, if at this point
the featuretype could be determined unambiguously, this
featuretype was assigned. In other cases, where the fea-
turetype was not determined unambiguously, the read
was designated as “Ambiguous” (Figure S1 in Additional
file 1).
For further analyses, the alignments were processed
and tables enumerating the featuretype, unique se-
quence, and count were created. This process enabled
the analyses of sequence lengths split out by featuretype,
and the analyses of fractions of RNA types per sample.
For the analysis of differential expression of specific
miRNA, the featuretype of miRNAs was further refined
to resolve the miRNA name. Analogously, for detailed
analysis of tRNAs and repeats, the featuretypes of these
two classes were further refined to include the tRNA
anti-codon and repeat family, respectively.
Correlations of samples
Correlations were only performed on genes which had at
least a total number of 15 reads over the cell samples, or
five reads over the exosome samples. Counts were normal-
ized using the trimmed-mean-of-M-values normalization.
Log values were calculated, and log values over zero were
imputed per sample, by taking the lowest nonzero normal-
ized value, dividing by two, and taking the log of that
value (i.e. zero counts were imputed by an estimation of
the lower limit of detection). Pearson correlation coeffi-
cients between the samples were calculated. In heat-
maps, genes were clustered by their standardized
euclidean distance, and samples were clustered by their
correlation coefficients.
tRNA/mRNA 3′ UTR complementarity analysis
A nonredundant list of tRNA fragment sequences was
made from the 20 most abundant tRNA fragments per
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pared using GENCODE v15 transcript annotations (only
for transcripts having a complete CDS annotation). tRNA
fragment sequences were searched for complementarity to
3′ UTRs using BLAST (blastn v.2.2.25), with parameters
allowing only ungapped, complementary hits (“-u T -S 2”),
seed length 6, and an adjusted effective search space size
which was set to the total genomic length spanned by the
3′ UTRs used in the database (to adjust for overlapping 3′
UTRs originating from the same genomic sequence). The
maximum allowed e value was 1.0. For each hit, the con-
servation of the genomic region that matched to the tRNA
was inspected using phyloP 100-way data (obtained from
UCSC tracks, dd. 20MAR2015). Additionally, the conser-
vation of the matching region relative to the shortest over-
lapping 3′ UTR was calculated.
Statistical analyses
All statistical analyses were carried out in R software
(http://www.r-project.org/). Differential expression was
determined using the exactTest routine from the edgeR
package [48] and common library dispersions. Counts
were normalized using the supplied trimmed-mean-of-
M-values algorithm, except in the analysis of high-level
feature types (e.g. “miRNA”, “piRNA”, “repeat”), in which
case total library sizes were used to normalize.
Research was carried out in compliance with the
Helsinki Declaration and all experimental protocols were
approved by the Ethical Committee of the VU University
Medical Center and of the Rizzoli Orthopaedic Institute.
Results
Mesenchymal stem cells from adipose tissue and bone
marrow release exosome-like EVs enriched in small RNAs
To study the mesenchymal stem cell-released EVs we
isolated primary adult MSCs from human bone marrow
(BMSCs, n = 4) and adipose tissue (ASCs, n = 3) (Figure
S2 in Additional file 1). Early passage MSCs (passages
0–2) were expanded in exosome-depleted FBS or PL to
support in vitro expansion [36].
The MSC endosomal compartment was analyzed by im-
munofluorescence and by EM. The immunofluorescent
staining showed high punctate expression of CD63, which
was mainly localized in nonacidic vesicles in the perinuclear
region of the cells, as determined by lysotracker (Fig. 1a,
top left). The early endosome antigen A1 (EEA1) staining
highlighted the presence of numerous early endosomes dis-
tributed throughout the cell body (Fig. 1a, bottom left).
However, despite the expression of endosomal markers, the
ultrastructure of the stem cells revealed relatively low num-
bers of late endosomes with internal vesicular structures,
suggestive of MVB-like compartments and/or secretory
lysosomes. These compartments had a diameter of about500 nm and enclosed 40–100 nm intraluminal vesicles
(Fig. 1a, right). The low abundance of MVB-like organelles
detectable by EM suggests that the high amount of CD63
observed in the perinuclear space of MSCs is associated
with intracellular membranes not related to MVBs.
EVs were isolated by differential centrifugation as de-
scribed previously [39] and their purity was confirmed
by EM and western blotting for CD63 and CD81. Cyto-
chrome C was assessed to exclude contamination by
apoptotic bodies (Fig. 1b). Although differential centrifu-
gation is the most commonly used method to isolate
exosomes from culture supernatant [49], it is not pos-
sible to rule out the presence of other types of EVs in
the exosome preparations when using this procedure.
However, because our preparations obtained by ultra-
centrifugation seem to be enriched for exosomes in
terms of size, shape, and tetraspanin content, we con-
sider these MSC-EVs as “exosomes”. To exclude poten-
tial contamination of MSC-exosome preparations by PL
or FBS-derived EVs, we analyzed CD63 and CD81 in
exosome-depleted culture media subjected to differential
centrifugation. Since no CD63 was detectable, we con-
cluded that our preparations contained mainly MSC-
derived exosomes (Figure S3A in Additional file 1).
To define the small RNA composition of the MSC
exosomes we degraded any unprotected RNA in exo-
some preparations by adding exogenous RNase A. Sub-
sequently, we isolated cellular and exosomal RNA,
which was subjected to Bioanalyzer profiling. The small
RNA profile of exosomes revealed characteristic peaks
between 20 and 70 nucleotides, suggestive of the pres-
ence of miRNAs and tRNAs. The size distribution in
cells was more heterogeneous and included longer tran-
scripts (Fig. 1c). We constructed cDNA libraries of MSC
cellular and exosomal RNA molecules with a length
ranging between approximately 15 and 90 nucleotides
(Figure S3B in Additional file 1).
We observed that early passage primary MSCs contain
relatively few MVBs, which suggests that these cells se-
crete relatively few exosomes compared with other cell
types [23, 50, 51]. However, MSC-released exosomes in-
corporate a small RNA population that is protected from
exogenous RNases.
Mesenchymal stem cells and their exosomes have a
different RNA composition
The sequencing of the libraries yielded a total of 25 mil-
lion reads. The cell samples showed a wide distribution
of read length, with a predominant peak around 22 nu-
cleotides (Fig. 2a), regardless of the tissue origin and
donor. Exosomes released by ASCs had a major peak be-
tween 31 and 36 nucleotides, while BMSC exosome
samples showed two different profiles and were there-




































Fig. 1 ASCs and BMSCs contain relatively few MVBs and release exosome-like vesicles enriched in small RNAs. a Immunofluorescent staining of
CD63 (top left) and EEA1 (bottom left), and ultrastructure of MVB-like endosomes (right) in ASCs and BMSCs. b Transmission electron microscopy
micrographs of exosomes isolated from ASCs and BMSCs (left); and western blot for CD63, CD81, and cytochrome C in cells and corresponding
exosomes (right). c Bioanalyzer small RNA profile of cells and exosomes showing enrichment of 20–70 nucleotide small RNAs in exosomes. ASC
adipose-derived mesenchymal stem cell, BMSC bone marrow-derived mesenchymal stem cell, EEA1 early endosome antigen A1, exo exosome
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that of ASC, while BMSC II exosomes displayed add-
itional peaks at 15 and 70 nucleotides. In order to assess
the variability among samples we performed an unsuper-
vised hierarchical clustering analysis. Clustering analysis
revealed a strong similarity among MSC samples irre-
spective of the stem cell source (Fig. 2b). Interestingly,
however, when looking at the exosome preparations,
ASC samples cluster tightly together, while BMSC I and
BMSC II exosome samples appear dissimilar from each
other. In accordance, the correlation analysis (Fig. 3a) in-
dicated a strong correlation among cellular samples
(0.87 <r <0.94). This correlation decreased whencomparing exosome libraries: the Pearson coefficient
within the BMSC I and BMSC II subtypes was 0.90 and
0.87 respectively, while it ranged from 0.66 and 0.73 be-
tween the two subgroups. Among ASC exosomes the
coefficient ranged from 0.84 to 0.88, while collectively
was between 0.65 and 0.84 between ASC and BMSC
exosomes.
The relatively low correlation between the two sub-
types of BMSC exosomes prompted us to investigate
whether the producing cells may represent different dif-
ferentiation stages. Because MSCs can spontaneously
undergo osteogenic differentiation during in-vitro expan-
sion [52], we analyzed the expression of early osteogenic
Fig. 2 MSCs and their exosomes display a different small RNA composition. a Length distribution of RNAseq aligned reads in ASCs and BMSCs
and corresponding exosomes (one representative donor). b Unsupervised hierarchical clustering analysis of MSCs and exosomes based on the
total small RNA content. ASC adipose-derived mesenchymal stem cell, BMSC bone marrow-derived mesenchymal stem cell, exo exosome
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collagen type 1 alpha 1 (COL1A1)—and of the stemness-
related genes SOX2, POU5F1A/B, and Nanog by quantita-
tive PCR (Fig. 3b). While we did not observe differences
in the expression of bone-related genes, BMSC II subtype
cells had elevated expression of Sox2, POU5F1A/B, and
Nanog as compared with the other subtypes (ANOVA
test, Fisher’s PLSD correction: p <0.05 BMSC II vs. ASC
and BMSC II vs. BMSC I for Sox2, and POU5F1A/B, and
BMSC II vs. ASC for Nanog). The different expression
levels of the pluripotency genes reflecting the stemness
of the MSCs might explain the dissimilarity in exosome
small RNA composition.The correlation matrix analysis (Fig. 3a) highlighted a
weak correlation between cells and corresponding exo-
somes (r ≤0.57). This implies that exosomes do not
strictly reflect the RNA composition of the cells of ori-
gin, but selectively incorporate a variety of RNA species.
Indeed, we observed enrichment of distinct RNA classes
in cells while others were overrepresented in exosomes
(Fig. 4a, b). In all MSC samples, miRNAs and small nu-
cleolar RNAs (snoRNAs) were the most abundant clas-
ses of RNA in the cells, although their proportion was
variable independently of the tissue source (19–49 %
and 21–49 %, respectively) (Fig. 4a). These two classes
together accounted for 64–71 % of the entire cellular
Fig. 3 Exosomes released by MSCs at different stages of differentiation correlate moderately with each other. a Correlation matrix of MSC and
exosome samples. b Relative expression levels of early osteogenic differentiation (top) and multipotency (bottom) genes analyzed by quantitative
PCR. Data were normalized to GAPDH. BMSC II express higher levels of Sox2 (ANOVA test: p = 0.006; Fisher’s PLSD test: p = 0.02 BMSC II vs. ASC,
p = 0.03 BMSC II vs. BMSC I), POU5F1A/B (ANOVA test: p = 0.01; Fisher’s PLSD test: p = 0.03 BMSC II vs. ASC, p = 0.01 BMSC II vs. BMSC I) and
Nanog (ANOVA test: p = 0.03; Fisher’s PLSD test: p = 0.056 BMSC II vs. ASC) compared with the other subtypes. ALP alkaline phosphatase, ANOVA
analysis of variance, ASC adipose-derived mesenchymal stem cell, BMSC bone marrow-derived mesenchymal stem cell, COL1A1 collagen type 1
alpha 1, exo exosome, GAPDH glyceraldehyde 3-phosphate dehydrogenase, Fisher's PLSD Fisher's Protected Least Significant Difference
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Fig. 4 Mesenchymal stem cells and their exosomes have a different RNA class distribution. a Relative distribution of overrepresented RNA species in MSCs
and exosomes. b Differential representation of RNA classes in MSC exosomes versus cells ordered by logFC. ASC adipose-derived mesenchymal stem cell,
BMSC bone marrow-derived mesenchymal stem cell, exo exosome, snoRNA small nucleolar RNA, logFC log fold-change, FDR false discovery rate
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(5–11 %), and rRNAs (up to 8 %). In contrast, exosome
libraries were highly enriched in the class of tRNAs,
which represented >50 % of total small RNAs in
adipose-derived exosomes and 23–35 % in bone marrow
exosomes, and repeats, ranging from 17–30 % in adi-
pose exosomes to 24–40 % in bone marrow exosomes
(Fig. 4a). The dominance of tRNAs in exosomes is con-
sistent with their function and abundance in the cellu-
lar cytoplasm. Other represented classes in exosomes
were miscellaneous RNAs, rRNAs, and miRNAs, the
latter representing only 2–5 % of the small RNA reper-
toire. In sharp contrast with that observed in MSC li-
braries, snoRNAs only represented a very small
proportion of the exosomal RNA content (<0.6 %).
In summary, our data indicate that miRNAs and snoR-
NAs are significantly enriched in the cells (miRNA:
logFC 3.35, FDR 3.3 × 10–10; snoRNA: logFC 6.65, FDR
4.9 × 10–27) while tRNAs and repeats form a defined
pool of RNAs heavily enriched in exosomes (tRNA:
logFC 2.46, FDR 1.59 × 10–6; repeats: logFC 1.88, FDR2.1 × 10–4), suggestive of preferential sorting and release.
The length distribution (Fig. 2a) showed predominant
peaks between 31 and 36 nucleotides in ASC and BMSC
I exosomes and additional peaks at around 15 and 70
nucleotides in BMSC II exosomes, suggestive of the
presence of full-length tRNA and tRNA fragments in
exosomes. Since tRNAs and tRNA fragments are in-
volved in translation regulation and RNA silencing,
these observations may point to a physiological link be-
tween post-transcriptional regulation and exosome bio-
genesis in MSCs [53, 54].Mesenchymal stem cell exosomes selectively incorporate
specific miRNAs
A substantial proportion of the cellular small RNA con-
tent in MSCs (19–49 %) is miRNA. However, this class
is underrepresented in exosomes (2–5 % of the total
small RNA) (Fig. 4a). Because of this discrepancy we in-
vestigated whether cells and exosomes share similar
miRNA content.
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RNA profile, unsupervised clustering analysis and correl-
ation analysis based on the miRNA content only re-
vealed high similarity within cellular samples (0.89 <r
<0.96), while exosome samples displayed greater vari-
ability (0.75 <r <0.90). Overall, the correlation between
cells and exosomes appears weak (Fig. 5a; and Figure
S4A in Additional file 1).
To assess whether miRNAs were present as precursors
or fully processed transcripts we looked at the length
distribution of the miRNA reads (Fig. 5b), and found
that in all MSC subtypes, both in exosomes and corre-
sponding cells, the vast majority of miRNA sequences
ranged between 20 and 25 nucleotides. Accordingly, the
sequencing coverage of the most represented miRNA
genes (UCSC genome browser) (Fig. 5c) predominantly
shows the presence of mature miRNAs mapping to the
5p and/or 3p arms of the precursor.
We then examined the relative proportion of individ-
ual miRNAs in the repertoire of total miRNA reads
(Fig. 6a; and Figure S4B in Additional file 1). Surpris-
ingly, the five most abundant miRNAs (miR-486-5p,
miR-10a-5p, miR-10b-5p, miR-191-5p, and miR-222-3p
in ASC exosomes; and miR-143-3p, miR-10b-5p, miR-
486-5p, miR-22-3p, and miR-21-5p in BMSC exosomes)
accounted for 43–59 % of the total miRNA reads. To
evaluate the relative distribution of miRNAs in cells and
exosomes, we ranked cellular and exosomal miRNA
based on the reads per million (rpm) values and com-
pared the 20 most represented miRNAs in cells and exo-
somes (Table 1). miR-21-5p, miR-22-3p, miR-10b-5p,
and miR-222-3p were among the most represented in
both cells and exosomes; however, various miRNAs
(shown in bold in Table 1) were only present either in
the list of cellular or in the list of exosomal highly repre-
sented miRNAs. We next asked whether specific miR-
NAs may be preferentially excreted or retained in the
cells. Figure 6b shows the top four miRNAs overrepre-
sented in exosomes compared with MSCs (logFC >7;
FDR <5 × 10–15). On the other hand, miR-34a-5p, miR-
34c-5p, miR-15a-5p, and miR-136-3p were significantly
overrepresented in cells compared with exosomes (logFC
>3; FDR <3 × 10–6) (Fig. 6c). The relative abundance of
these miRNAs is shown in Figure S4C in Additional file
1. Altogether, the nonrandom distribution of miRNAs is
consistent with a sorting mechanism for disposal of “un-
used” small RNAs or for communication with the sur-
rounding environment as shown in other cell types [55].
tRNA-derived RNA fragments are highly represented in
MSC exosomes
The dramatic overrepresentation of tRNA sequences in
MSC exosomes prompted us to investigate which tRNAs
were the most represented and whether these couldbe functional processed transcripts or degradation
products.
Our analysis revealed that generally the adult MSC
subtypes have similar tRNA profiles irrespective of the
tissue source (Fig. 7a, top). tRNA CTC (Glu) was highly
represented both in ASCs and in BMSCs, accounting for
43–72 % of the total tRNA reads. In order to exclude
potential experimental biases leading to high representa-
tion of one specific tRNA sequence, we also analyzed
the tRNA profile obtained by small RNAseq in an unre-
lated cell type—i.e. lymphoblastoid cells (LCLs) (Figure
S5A in Additional file 1). Interestingly, we found a very
distinct tRNA distribution in these cells suggesting that,
similar to miRNAs, tRNA profiles may be useful as indi-
cators of tissue origin. Overall, exosomal tRNA profiles
appeared distinct from the cellular profiles (Figure S6 in
Additional file 1) and displayed more intergroup vari-
ability (Fig. 7a, bottom). The five most prevalent tRNA
sequences in MSC exosomes accounted for 87–97 % of
the total exosomal tRNA pool (consisting of 40–54 dif-
ferent acceptors). Interestingly, while in BMSCs and
LCLs the most abundant tRNAs in cells and exosomes
clearly correspond, the most abundant tRNA in ASC
exosomes, tRNA GCC (Gly), only represented a small
fraction (5 %) of the total cellular tRNA (Fig. 7a). Moreover,
this tRNA was overrepresented in ASC exosomes com-
pared with BMSC exosomes (logFC 3.8; FDR 1.1 × 10–7)
(Figure S5B in Additional file 1).
To investigate whether MSC libraries contain full-length
tRNAs or processed transcripts we analyzed the length
distribution of the tRNA reads (Fig. 7b). Surprisingly, both
in cells and exosomes, tRNA fragments constitute a con-
siderable fraction of the total tRNA. Although MSCs from
both tissue origins display a broad range of tRNA lengths,
exosomal tRNA sequences have specific fragment sizes.
ASC exosomes and BMSC I exosomes mainly contained
fragments of 30–35 nucleotides, whereas BMSC II exo-
somes also show a dominant peak at 70–75 nucleotides.
Intrigued by these findings we zoomed into the genomic
coverage and length distribution of the most represented
tRNA genes (Fig. 7c; and Figure S5C in Additional file 1).
Strikingly, while at the cellular level adipose and bone
marrow MSCs contain the full-length form of the most
abundant tRNA, tRNA CTC (Glu), exosomes released by
ASC and BMSC I exosomes consistently display the 33-
nucleotide 5′ halves of the most abundant sequences
(Fig. 7c; and Figure S5C in Additional file 1). BMSC II
exosomes that are produced by cells with high expression
of pluripotency factors seem to preferentially enclose the
full-length form of tRNA CTC (Glu), and the 33-
nucleotide fragments of other abundant tRNA species
(Figure S5C in Additional file 1). The remarkable differ-
ences in tRNA composition observed between adipose
and bone marrow exosomes warrant future investigations
Fig. 5 MSCs and their exosomes display a different miRNA repertoire. a Unsupervised hierarchical clustering analysis of MSCs and their exosomes
based on the miRNA content. b Length distribution of miRNA reads in ASC and BMSC I and BMSC II cells and exosomes (one representative
donor). c Sequence coverage of highly represented miRNA genes (based on UCSC genome browser custom tracks) showing a predominant
presence of mature forms (one or both miRNA arms) in MSCs and exosomes. Y axis indicates the normalized counts (rpm). ASC adipose-derived
mesenchymal stem cell, BMSC bone marrow-derived mesenchymal stem cell, exo exosome
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Fig. 6 MSC exosomes selectively incorporate specific miRNAs. a Relative proportion of miRNAs in the repertoire of total miRNA reads. The five
most abundant miRNAs represent 50 % of the total miRNA reads. b Overrepresented and c underrepresented miRNAs in MSC exosomes as
compared with producing cells (LogFC >3; FDR <0.0002). ASC adipose-derived mesenchymal stem cell, BMSC bone marrow-derived mesenchymal
stem cell, exo exosome
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sources and at different stages of differentiation.
Although the function of tRNA fragments and tRNA
halves in mammalian cells is still largely unknown, a
miRNA/siRNA (small interfering RNA)-like function for
these tRNA species has been recently suggested [56].
Here we performed a bioinformatic analysis to evaluate
the antisense complementarity of the most abundant
tRNA species in cells and exosomes to the 3′ UTRs of
annotated protein-coding transcripts. We found a group
of putative candidate targets (Table 2; and Additional file
2), many of which have undefined biological function.Interestingly, among the potential targets we found fac-
tors involved in stem cell self-renewal and MSC differen-
tiation, such as TFCP2L1, RUNX2, and SOX11, the
transforming growth factor-beta (TGFβ) signaling medi-
ator SMAD3, and immune-related factors such as
HHLA2, EMR2, and TRIM62.
Discussion
The administration of MSC-EVs is advantageous over
cell-based therapy because it eliminates the safety con-
cerns associated with the injection of multipotent cells
into patients [12]. MSC-secreted exosomes have recently
Table 1 Most abundant miRNAs in MSC exosomes and cells
Rank Most represented miRNA in exosomes Most represented miRNA in cells
miRNA rpm ASC exosomes miRNA rpm ASC cells
1 miR-486-5p 172,837 miR-21-5p 145,332
2 miR-10a-5p 117,453 miR-22-3p 92,902
3 miR-10b-5p 104,447 miR-10b-5p 82,089
4 miR-191-5p 92,545 miR-222-3p 74,725
5 miR-222-3p 49,405 miR-143-3p 73,794
6 miR-22-3p 37,205 let-7a-5p 71,686
7 let-7a-5p 28,814 miR-10a-5p 44,303
8 miR-21-5p 27,233 miR-92a-3p 33,827
9 miR-127-3p 27,071 let-7f-5p 33,248
10 miR-143-3p 22,579 let-7i-5p 22,624
11 miR-99b-5p 21,471 miR-127-3p 17,303
12 miR-100-5p 18,836 miR-148a-3p 17,109
13 miR-92a-3p 18,217 miR-26a-5p 16,127
14 let-7f-5p 17,589 miR-92b-3p 14,852
15 miR-92b-3p 16,124 miR-21-3p 14,548
16 miR-26a-5p 13,207 miR-221-3p 12,481
17 miR-146a-5p 12,212 miR-16-5p 11,544
18 miR-4485 10,656 miR-100-5p 11,180
19 miR-146b-5p 10,,558 miR-31-5p 9521
20 miR-151a-3p 10,262 miR-411-5p 8051
miRNA rpm BMSC exosomes miRNA rpm BMSC cells
1 miR-143-3p 124,950 miR-143-3p 185,884
2 miR-10b-5p 103,485 miR-21-5p 150,993
3 miR-486-5p 91,274 miR-22-3p 105,358
4 miR-22-3p 74,730 let-7a-5p 91,387
5 miR-21-5p 47,445 miR-10b-5p 42,729
6 miR-222-3p 46,094 miR-222-3p 38,076
7 miR-191-5p 45,054 miR-27b-3p 35,496
8 miR-100-5p 41,668 let-7f-5p 29,054
9 let-7a-5p 38,486 let-7i-5p 21,993
10 miR-99b-5p 29,011 miR-26a-5p 21,934
11 miR-92a-3p 24,941 miR-100-5p 21,157
12 miR-127-3p 21,319 miR-127-3p 14,836
13 let-7f-5p 21,203 miR-148a-3p 12,789
14 miR-92b-3p 20,938 miR-92b-3p 12,306
15 miR-423-5p 19,807 miR-92a-3p 11,840
16 miR-10a-5p 14,716 miR-191-5p 11,384
17 miR-27b-3p 13,604 miR-21-3p 11,372
18 let-7i-5p 11,997 miR-125b-5p 10,699
19 miR-28-3p 10,554 let-7b-5p 9603
20 miR-125b-5p 10,378 miR-16-5p 9583
miRNAs present only in the list of cellular or in the list of exosomal miRNAs are highlighted in bold
ASC adipose-derived mesenchymal stem cell, BMSC bone marrow-derived mesenchymal stem cell, miRNA microRNA, MSC mesenchymal stem cell, rpm reads
per million
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Fig. 7 tRNA-derived RNA fragments are highly represented in MSC exosomes. a Relative distribution of highly represented tRNAs in MSCs and
respective exosomes. b Length distribution of tRNA sequencing reads in ASC and BMSC I and II cells and exosomes. c Sequence coverage of
highly represented tRNA genes (based on UCSC genome browser custom tracks). Y axis indicates the normalized counts (rpm). ASC adipose-derived
mesenchymal stem cell, BMSC bone marrow-derived mesenchymal stem cell, exo exosome
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Table 2 Complementarity analysis of tRNA species to 3′ untranslated regions of protein-coding genes
Query Query sequence Hit length e value Bitscore Gene name Conservation value Normalized
conservation value
tRNA; Glu; CTC AGTGGTTAGGATTCGGC
GCTCTCACCGCCGCGGCCC
14 0.19 28.2 GOLGA6A 0.510 0.970
tRNA; Glu; TTC TCCCTGGTGGTCTAGTG
GCTAGGATTCGGCGCTTT
24 0.012 32.2 TFCP2L1 0.146 1.067
14 0.19 28.2 NELF -0.303 0.962
17 0.74 26.3 KIAA0513 -0.367 1.013
13 0.74 26.3 ZBTB45 -0.447 0.950
13 0.74 26.3 HHIPL1 -1.103 0.808
13 0.74 26.3 HSP90AA1 -0.248 0.982
13 0.74 26.3 TULP4 1.937 1.345
13 0.74 26.3 SMAD3 0.259 1.001
13 0.74 26.3 RPS19 -0.474 0.984
13 0.74 26.3 ZNF662 0.140 0.990
13 0.74 26.3 AC104841.2 2.810 1.542
tRNA; Gly; GCC GCATGGGTGGTTCAG
TGGGAGAATTCTCGCCT
18 0.19 28.2 PHF13 0.042 0.914
14 0.19 28.2 KDSR -0.243 0.904
14 0.19 28.2 PLAGL2 0.634 0.881
13 0.74 26.3 NOX5 -0.231 0.982
13 0.74 26.3 EPM2AIP1 0.373 0.996
13 0.74 26.3 GTF3C1 -0.476 1.095
13 0.74 26.3 GPR110 0.293 1.053
13 0.74 26.3 TPI1 0.241 0.971
13 0.74 26.3 PPP2R1B -0.302 0.875
13 0.74 26.3 LUZP2 0.125 0.998
13 0.74 26.3 VPS41 -0.243 0.977
13 0.74 26.3 SSR1 0.187 1.025
13 0.74 26.3 RUNX2 1.358 0.956
13 0.74 26.3 MAP1LC3B -0.254 0.890
GCATGGGTGGTTCA
GTGGTAGAATTCTCGCCG
14 0.19 28.2 GCM1 0.127 1.032
17 0.74 26.3 SLC2A13 0.507 0.983
13 0.74 26.3 GTF3C1 -0.476 1.095
13 0.74 26.3 HHLA2 -0.075 1.004
13 0.74 26.3 TPI1 0.241 0.971
13 0.74 26.3 PEG10 -0.126 0.806
13 0.74 26.3 EMR2 -0.166 0.954
13 0.74 26.3 SSR1 0.187 1.025
11 0.7 22.3 THAP5 0.155 0.979
11 0.7 22.3 THAP5 0.393 1.029
GCATGGGTGGTTCA
GTGGTAGAATTCTCGCCTG
14 0.19 28.2 GCM1 0.127 1.032
17 0.74 26.3 SLC2A13 0.507 0.983
13 0.74 26.3 GTF3C1 -0.476 1.095
13 0.74 26.3 HHLA2 -0.075 1.004
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Table 2 Complementarity analysis of tRNA species to 3′ untranslated regions of protein-coding genes (Continued)
13 0.74 26.3 TPI1 0.241 0.971
13 0.74 26.3 PEG10 -0.126 0.806
13 0.74 26.3 EMR2 -0.166 0.954
13 0.74 26.3 SSR1 0.187 1.025
11 0.73 22.3 THAP5 0.155 0.979
11 0.73 22.3 THAP5 0.393 1.029
GCATTGGTGGTTCAGTGGTAGAATTCT
CGCCTGCCACGCGGGAGGCCCGGGT
20 0.012 32.2 SOX11 0.180 0.752
14 0.19 28.2 GCM1 0.127 1.032
17 0.74 26.3 SLC2A13 0.507 0.983
17 0.74 26.3 FAM57B -0.158 0.849
13 0.74 26.3 HHLA2 -0.075 1.004
13 0.74 26.3 C1orf159 -0.663 0.984
13 0.74 26.3 KLC2 -0.224 0.835
13 0.74 26.3 PEG10 -0.126 0.806
13 0.74 26.3 DRG2 -0.468 0.817
13 0.74 26.3 VPRBP 1.514 0.913
13 0.74 26.3 TRIM62 -0.098 0.921
13 0.74 26.3 EMR2 -0.166 0.954
13 0.74 26.3 ANXA8L2 2.926 1.223
Baglio et al. Stem Cell Research & Therapy  (2015) 6:127 Page 16 of 20been shown to improve therapy-refractory graft-versus-
host disease [11] and to promote organ healing in vari-
ous preclinical models [21, 32, 33]. Comprehensive
characterization of these vesicles is therefore a critical
step in understanding their biological activity to
maximize clinical utility.
MSCs have been described before as prolific producers
of exosomes when compared with some other cell types
[57]. However, this conclusion was based on the use of
myc-transformed (immortalized) human embryonic stem
cell-derived MSCs [58], which was required to overcome
the limited in-vitro expansion potential. Because immor-
talized cells may secrete pro-oncogenic material via EVs
[59], the clinical usefulness of these vesicles is uncertain.
In addition, immortalized MSCs may produce EVs with
an altered content, casting additional doubt as to
whether these EVs are representative of their natural
counterparts [60]. We show here that unmanipulated
MSCs in culture produce few EVs with exosome charac-
teristics. Accordingly, MSCs in culture possess relatively
few prototypical MVBs compared with most cell types
analyzed thus far in our laboratory [23, 50]. Although
MSC exosomes have the same morphology as exosomes
from B-cell blasts and carry typical marker proteins, they
may differ in compartmentalization, biogenesis, and
therefore RNA composition. Moreover, we presume that
factors such as tissue origin (adult or embryonic) andstemness could influence both exosome production and
content.
The very low intragroup and intergroup variability
among MSC samples indicates that donor-specific char-
acteristics and the tissue-specific microenvironment do
not significantly influence the small RNA expression
profile of the cells. However, important differences
emerged when comparing EV preparations. The variabil-
ity between ASC and BMSC EVs suggests that the
tissue-specific microenvironment might influence the
exosomal sorting of the MSCs. The intragroup variability
indicates that cell-intrinsic factors, such as the differenti-
ation status of the cells, might dictate which signals are
conferred by the cells, as previously reported for cyto-
kines and growth factors [61, 62].
Although most studies show that miRNAs only repre-
sent a small fraction of exosomal RNA [28, 63, 64], miR-
NAs transferred via exosomes can be functional in
repressing their target in vitro and in vivo [23–27]. In
our analysis, we found that the five most abundant miR-
NAs in MSC exosomes accounted for 50 % of the total
miRNA reads. Thus, specific miRNAs present in high
amounts might have physiological effects. In a previous
study, Chen et al. [65] showed that particles secreted by
human embryonic stem cell-derived MSCs are enriched
in pre-miRNAs. In contrast, our study reveals that adult
MSC exosomes mainly contain mature transcripts.
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and adult MSCs preferentially enclose different miRNA
forms, conditioned medium as a whole presumably con-
tains heterogeneous populations of RNA when compared
with exosomes purified by differential ultracentrifugation,
as analyzed in this study. Possibly, the pre-miRNAs are
not released in association with exosomes but are incor-
porated into vesicles of different nature. Although there is
a substantial similarity between the most represented
miRNAs in ASC and BMSC exosomes, their relative pro-
portions are different, raising the possibility that ASCs
and BMSCs might deliver different information into their
microenvironments. Some of these miRNAs have been
implicated in MSC biology [66]. miR-486 is involved in
ASC replicative senescence [67], miR-143 has been related
to the immune modulatory function of MSCs [68], miR-
10a and miR-22 are important regulators of MSC differen-
tiation [69, 70], and miR-10b promotes the migration of
mouse BMSCs [71]. The release of these miRNAs by
ASCs and BMSCs could play a role in stem cell niche
maintenance by controlling and fine-tuning proliferation,
differentiation, and homing. In addition, multiple miRNAs
highly represented in adult MSC exosomes regulate cell
cycle progression and proliferation (miR-191, miR-222,
miR-21, let-7a), and modulate angiogenesis (miR-222,
miR-21, let-7f) and endothelial cell differentiation (miR-
6087) [72–74]. The uptake of these miRNAs at sites of in-
jury might promote the proliferation of multiple cell types
and stimulate the formation of new blood vessels for tis-
sue repair.
While most of the focus on functional small RNAs in
exosomes has been on the class of miRNAs, in contrast
with what was previously reported for immune and
neuronal cells [28, 63], MSC exosomes are highly
enriched in tRNAs, specifically tRNA halves, and repeats
compared with the producing cells.
Recent findings suggest that tRNA pools in proliferating
cells versus differentiating cells are distinct. Importantly,
it was noted that genes involved in cell-autonomous
functions carry codons corresponding to proliferation-
associated tRNAs, while genes linked to multicellularity
require differentiation-associated tRNAs [75]. Therefore it
would be very interesting to investigate the correlation
between the most abundant tRNA species produced and
released via exosomes by MSCs and the cellular protein
composition, and how this might change upon activation
of specific differentiation programs.
Post-transcriptional processing of tRNAs into tRNA
fragments is a nonrandom evolutionary conserved mech-
anism [53, 54, 76]. Strikingly, tRNA fragments of defined
sizes are highly represented in adult MSCs and tRNA
halves appear to be massively sorted into MSC exosomes.
The 14–30-nucleotide tRNA-derived RNA fragments
(tRFs) are known to associate with Argonaute proteinsand have similar properties to miRNAs [53]. Moreover,
these fragments can define transformed cells [77]. The
function of tRNA halves in mammalian cells, however,
is largely unknown. Protein biosynthesis inhibition in
response to stress conditions has been initially proposed
as the most plausible explanation for tRNA cleavage.
However, the two halves of the tRNA are usually un-
equally stable, suggesting more complex roles for these
tRNA pieces [54]. More recently, 5′ halves have been
implicated in stress-induced translation inhibition and
stress granule formation [78]. In MSCs it seems that
tRNA halves are expressed at relatively high levels
under standard culture conditions, possibly indicating
physiological functions.
We found that ASC exosomes predominantly carry
tRNA halves and are virtually devoid of full-length tran-
scripts. BMSC exosomes have two different tRNA length
profiles that seem to be related to differentiation status.
Indeed, BMSCs expressing a high level of key stemness
markers (BMSC II) package both full-length transcripts
and 33-nucleotide fragments, while more differentiated
cells (BMSC I) display the same tRNA length profile as
ASC exosomes. Interestingly, however, the most abundant
tRNAs in exosomes do not always correspond to those in
cells, suggesting that cells can sort specific tRNAs perhaps
as a mechanism for gene expression regulation. Analyzing
the genomic coverage of the most abundant tRNA reads
we found that ASC and BMSC I exosomes consistently
display the 5′ halves of the most represented tRNA se-
quences, tRNA GCC (Gly) and CTC (Glu), respectively.
The 5′ half of tRNA CTC (Glu) was recently shown to act
in a miRNA/siRNA-like fashion to silence target mRNAs
[56], although putative target transcripts for this and other
fragments have not yet been identified.
The complementarity analysis of the most abundant
tRNA species in cells and exosomes to the 3′ UTRs of
protein-coding genes highlighted interesting putative tRNA
targets involved in stem cell renewal, differentiation, and
immune modulation. For instance, we found: TFCP2L1, a
transcription factor involved in stem cell self-renewal [79];
RUNX2 and SOX11, master transcription factors in
MSC differentiation [80, 81]; SMAD3, mediator of TGF-β-
induced proliferation, differentiation, and survival; RPS19,
involved in erythropoietic differentiation and proliferation
[82]; and immune-related factors and inflammation
mediators such as HHLA2, EMR2, and TRIM62 [83–85].
Further studies will be required to elucidate the biological
function of the tRNA fragments and to evaluate whether
their release via exosomes is involved in orchestrating
tissue architectures.
Conclusions
The role of EV-transferred RNA in physiological pro-
cesses in vivo remains unclear, partly because the
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required for causing physiological changes in target cells
is difficult to predict, and is likely to involve many fac-
tors. One recent hypothesis is that the most abundant
and enriched RNA species in EVs play a dominant role.
Using RNAseq analysis we could demonstrate that the
most abundant and enriched small RNAs in adult MSC
exosomes are defined tRNA species. Moreover, adipose
and bone marrow MSC subtypes secrete different tRNA
species that may be relevant for clinical applications. Fu-
ture studies should focus on how these tRNA molecules
are transported by MSC exosomes under physiological
conditions and whether they influence their microenvir-
onment in a cell type-dependent manner.
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transcripts.
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